Neutrophils: "Neu players" in antibody therapy?

Blood

Volumn 122, Issue 18, 2013, Pages 3093-3094

  Beers, Stephen A ^a   Glennie, Martin J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CLODRONIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB; VASCULOTROPIN ANTIBODY;

ADOPTIVE TRANSFER; ANTIBODY THERAPY; BREAST CARCINOMA; CELL POPULATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; LEUKOCYTE ACTIVATION; LYMPHOMA; MACROPHAGE; MELANOMA; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR REJECTION;

EID: 84888234973     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-525451     Document Type: Review

References (10)

1. Albanesi M, Mancardi DA, Jönsson F, et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood. 2013;122(18):3160-3164.
2. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112(4):1205-1213.
3. Biburger M, Aschermann S, Schwab I, et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity. 2011;35(6):932-944.
4. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191-5201.
5. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2006;24(18):2885-2890.
6. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758.
7. van der Kolk LE, Grillo-López AJ, Baars JW, van Oers MH. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia. 2003;17(8):1658-1664.
8. van Egmond M, Bakema JE. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol. 2013;23(3):190-199.
9. Pascal V, Laffleur B, Debin A, et al. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica. 2012;97(11):1686-1694.
10. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519-531.